Patent ID: 8614332

Claim:
A method for modulating glucokinase activity, which comprises administering to a mammalian patient in need thereof a therapeutically effective amount of a compound having the structure: or a pharmaceutically acceptable salt thereof, wherein: R 4 is selected from the group consisting of: —(CH 2 ) n —Z—(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z—(CH 2 ) m —PO(OR 7 )R 9 , and —(CH 2 ) n Z—(CH 2 ) m —PO—(R 9 )R 10 ; R 7 and R 8 are independently alkyl, or R 7 and R 8 can be cyclized into a ring where q=1, 2, or 3; R 9 and R 10 are independently selected from the group consisting of alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or R 9 and R 10 can be cyclized into a ring where q=1, 2, or 3, or where q=1, 2, or 3; or R 7 and R 9 can be cyclized into a ring where q=1, 2, or 3 or where q=1, 2, or 3; Z is a single bond, alkylene, or alkenylene wherein said alkylene or alkenylene may be optionally substituted with hydroxy, alkoxy, aminoalkyl, aminoaralkyl, aminoheteroaralkyl, aminoaryl, aminoheteroaryl, or carboxy; m is zero, 1, or 2; n is 1 or 2; R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, halogen and carboxy; X is a single bond; Y is R 3 —(CH 2 ) s —; s is zero; and R 3 is phenyl substituted with zero, 1, or 2 substituent groups independently selected: (a) —OR a wherein R a is: (i) alkyl, wherein said alkyl may be further substituted with at least one of halo, alkoxy or phenyl; (ii) phenyl, optionally substituted with —SO 2 R c wherein R c is alkyl; (iii) a 4- to 7-membered heterocyclo optionally substituted with —SO 2 R c wherein R c is alkyl; (iv) pyridinyl or pyrazinyl, optionally substituted with —C(═O)NR d R b or —SO 2 R c wherein R d and R b may join together with the N to which they are attached to form a 4- to 7-membered heterocyclo and R c is alkyl; and/or (b) —C(═O)R a wherein R a is a 4- to 7-membered heterocyclo.